Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the dose–response relationship of the recombinant glucagon‐like peptide‐1 (7‐36) amide (rGLP‐1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11‐h serum glucose profiles. Methods: In a double‐blind, parallel, placebo‐controlled trial, 47 patients were randomized to placebo or rGLP‐1 (1.25, 2.5, 5.0 or 8.5 pmol/kg/min) by CSCI for 7 days. On day 1 (pretreatment) and on day 8, patients underwent monitoring of fasting, postprandial, and 11‐h profiles of glucose and hormones. Results: Fasting serum glucose decreased by 76.2, 53.9, 37.0 and 22.7 mg/dl for the 8.5, 5.0, 2.5 and 1.25 pmol/kg/min rGLP‐1 groups, respectively, compared to a decrease of 1.1 mg/dl for placebo (p = 0.0002, 0.005, 0.064 and 0.27, respectively). Mean 11‐h serum glucose area under the curve decreased by 36.3, 23.3, 16.9 and 10.0% for 8.5, 5.0, 2.5 and 1.25 pmol/kg/min rGLP‐1, respectively, compared to no change for placebo (p = 0.0001, 0.0019, 0.012 and 0.14, respectively). Mean fasting C‐peptide increased dose dependently with rGLP‐1 (p = 0.0023 for the highest dose) and decreased with placebo. There were no serious safety concerns and no instances of hypoglycaemia. Conclusions: rGLP‐1 produced continuous improvements in glycaemic control across a broad dose range of up to 8.5 pmol/kg/min.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“These data are concordant with results obtained from a 6-week rGLP-1 infusion and a 1-week treatment with liraglutide [5,8].”
BackgroundResultInfluentialSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“This is at variance with results from acute studies [10].”
ResultSelf-citationDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · cited 1×
“It is now recognized that the optimal therapeutic effect of GLP-1 is achieved with regimens that provide sustained plasma levels of active peptide [2,3].”
Background
Cited by
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Self-citationTan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88
“GLP-1 (7-36) amide, PYY (3-36), andOXMwere purchased from Insight Biotechnology (London, United Kingdom).”
BackgroundMethodSelf-citationDeng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221108064 · Cited by 51
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“The insulinotropic properties of GLP-1 in T2DM patients, on the other hand, is well established and may completely restore glucose-induced insulin secretion [25,26].”
BackgroundSelf-citation
Metadata
- Authors
- Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-05-24
- Volume
- 13
- Issue
- 7
- Pages
- 639-643
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2023896406
- Cited by
- 25
- References
- 4
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01388.x
- The paper
- Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R. (2011). Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01388.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.